---
title: "Real-world use and outcomes of immune checkpoint inhibitors in the FAIR-ICI multicenter cohort"
id: "medrxiv-14-comprehensive-real-world-utilization-treatment-trajectories-and-outcomes-of"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-14-comprehensive-real-world-utilization-treatment-trajectories-and-outcomes-of"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.11.02.26367076v1?rss=1"
published_at: "2026-11-03T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Real-world use and outcomes of immune checkpoint inhibitors in the FAIR-ICI multicenter cohort
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-14-comprehensive-real-world-utilization-treatment-trajectories-and-outcomes-of
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.11.02.26367076v1?rss=1)
- **Published At:** 2026-11-03T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The FAIR-ICI cohort pooled electronic health record data from four Belgian hospitals to examine real-world use of **immune checkpoint inhibitors** across cancer types. - Investigators harmonized structured and unstructured data to the OMOP-CDM and used natural language processing to reconstruct treatment trajectories and outcomes. - The cohort included 3,231 patients treated with ICIs; 2,514 (77.8%) had metastatic disease at treatment. - Key endpoints evaluated were **overall survival** (OS), time on treatment (ToT), time to next treatment (TTNT), ICI discontinuation defined as a >12-week gap, and post-discontinuation survival. - Among metastatic patients, 568 (22.6%) discontinued ICI without receiving subsequent systemic therapy; median post-discontinuation OS was 21.4 months, with about 49.1% alive at 24 months. - ToT and TTNT were typically shorter than OS; melanoma exemplified this pattern (reported median OS 78 months, ToT 7 months, TTNT 26 months). - Real-world OS frequently trailed pivotal trial results. Performance status mattered: **ECOG** ≥2 conferred worse survival (adjusted HR 2.18 versus ECOG 0–1). - In NSCLC patients treated with pembrolizumab plus chemotherapy, survival for ECOG 0–1 approximated trial outcomes, while ECOG ≥2 survival was substantially lower. - FAIR-ICI includes a public interactive dashboard for aggregate exploration; patient-level data remain restricted per governance and ethics approvals. - The preprint authors noted FAIR-ICI as a scalable framework for future real-world evaluations, including treatment-related toxicity, but the manuscript is not peer-reviewed and underlying raw data are not publicly available without governance approvals.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=MLougCXCW114usPeC7ueceGRjiSjaEn8VluGIO_Xbvw-1793724640.9269567-1.2.1.1-4aXNqVju3kOk27WhbnjIKByHHHK9Z8RxJDLxbOFQ.GYGUkklAWJw0f4.9.kebX9Q) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.11.02.26367076v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Comprehensive real-world utilization, treatment trajectories, and outcomes of immune checkpoint inhibitors across cancer types: the multicenter FAIR-ICI cohort Linh T. Ha, Fabienne Ver Donck, Iege Bassez, Clara L. Oeste, Christof Vulsteke, Danielle Delombaerde, Dries Hens, Hans Prenen, Lieselot Croes, Astrid De Meulenaere, Philip R. Debruyne, Marthe Verhaert, Sandrine Aspeslagh, Nele Brusselaers, Annelies Verbiest doi: https://doi.org/10.64898/2026.11.02.26367076 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Linh T. Ha 1 University Hospital Antwerp; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Linh%2BT.%2BHa%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Ha%20LT&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ALinh%2BT.%2BHa%2B) Fabienne Ver Donck 2 LynxCare Clinical Informatics; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Fabienne%2BVer%2BDonck%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Ver%20Donck%20F&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AFabienne%2BVer%2BDonck%2B) Iege Bassez 2 LynxCare Clinical Informatics; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Iege%2BBassez%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Bassez%20I&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AIege%2BBassez%2B) Clara L. Oeste 2 LynxCare Clinical Informatics; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Clara%2BL.%2BOeste%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Oeste%20CL&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AClara%2BL.%2BOeste%2B) Christof Vulsteke 3 AZ Maria Middelares; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Christof%2BVulsteke%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Vulsteke%20C&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AChristof%2BVulsteke%2B) Danielle Delombaerde 3 AZ Maria Middelares; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Danielle%2BDelombaerde%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Delombaerde%20D&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ADanielle%2BDelombaerde%2B) Dries Hens 2 LynxCare Clinical Informatics; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Dries%2BHens%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Hens%20D&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ADries%2BHens%2B) Hans Prenen 1 University Hospital Antwerp; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Hans%2BPrenen%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Prenen%20H&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AHans%2BPrenen%2B) Lieselot Croes 1 University Hospital Antwerp; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Lieselot%2BCroes%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Croes%20L&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ALieselot%2BCroes%2B) Astrid De Meulenaere 3 AZ Maria Middelares; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Astrid%2BDe%2BMeulenaere%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=De%20Meulenaere%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAstrid%2BDe%2BMeulenaere%2B) Philip R. Debruyne 4 AZ Groeninge; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Philip%2BR.%2BDebruyne%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Debruyne%20PR&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3APhilip%2BR.%2BDebruyne%2B) Marthe Verhaert 5 University Hospital Brussels; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Marthe%2BVerhaert%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Verhaert%20M&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMarthe%2BVerhaert%2B) Sandrine Aspeslagh 5 University Hospital Brussels; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Sandrine%2BAspeslagh%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Aspeslagh%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ASandrine%2BAspeslagh%2B) Nele Brusselaers 6 University of Antwerp * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Nele%2BBrusselaers%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Brusselaers%20N&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ANele%2BBrusselaers%2B) Annelies Verbiest 1 University Hospital Antwerp; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Annelies%2BVerbiest%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Verbiest%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAnnelies%2BVerbiest%2B) * For correspondence: annelies.verbiest@uza.be * [Abstract](https://www.medrxiv.org/content/10.64898/2026.11.02.26367076v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1337375/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.11.02.26367076v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1337375/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.11.02.26367076v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1337375/1) * [Supplementary material](https://www.medrxiv.org/content/10.64898/2026.11.02.26367076v1.supplementary-material)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_data/node:1337375/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.11.02.26367076v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1337375/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.11.02.26367076v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1337375/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Background: Immune checkpoint inhibitors (ICIs) have transformed cancer treatment, yet evidence on their utilization, treatment trajectories, and effectiveness in routine clinical practice remains limited. We characterized real-world ICI use and outcomes across cancer types using the multicenter FAIR-ICI cohort and explored differences between real-world and pivotal trial outcomes. Methods: We conducted a retrospective cohort study of adults receiving ICIs across four Belgian hospitals. Structured and unstructured electronic health record data were harmonized using the Observational Medical Outcomes Partnership Common Data Model (OMOP-CDM) and natural language processing. We evaluated overall survival (OS), time on treatment (ToT), time to next treatment (TTNT), ICI discontinuation (>12-week treatment gap without re-initiation), and post-discontinuation survival. OS was descriptively compared with pivotal trials, and prognostic factors were assessed using multivariable Cox regression. An interactive public dashboard was developed to enable exploration of cohort characteristics, treatment patterns, and outcomes. Results: Among 3,231 ICI-treated patients, 2,514 (77.8%) had metastatic disease. Among metastatic patients, 568 (22.6%) discontinued ICI without subsequent systemic therapy. Median post-discontinuation OS was 21.4 months (95% CI 16.5-37.2), with 49.1% alive at 24 months. ToT and TTNT were generally shorter than OS, particularly in melanoma (median OS 78 months; ToT 7 months; TTNT 26 months). Real-world survival was frequently less favorable than in pivotal trials. ECOG >=2 was associated with poorer OS than ECOG 0-1 (adjusted HR 2.18, 95% CI 1.82-2.60). In NSCLC patients receiving pembrolizumab plus chemotherapy, survival with ECOG 0-1 more closely approximated trial outcomes, whereas survival with ECOG >=2 was substantially poorer. Conclusions: Real-world ICI treatment trajectories extend beyond active treatment, with some patients experiencing prolonged survival after discontinuation. Differences between real-world and trial outcomes highlight the importance of patient characteristics, particularly performance status, when interpreting trial evidence in routine care. FAIR-ICI provides a scalable framework for evaluating real-world immunotherapy effectiveness, treatment trajectories, and future investigations of treatment-related toxicity. ### Competing Interest Statement CV reports personal fees for invited speaking from Astellas, Ipsen, and MSD; personal fees for advisory board participation from Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi Sankyo, GSK, Janssen-Cilag, Merck, MSD, and Pfizer; personal fees for expert testimony from Athenum Partners; and institutional research funding from MSD for research on immune-related toxicities. PRD reports personal consulting fees from Astellas, Ipsen, and MSD; travel support from AstraZeneca, MSD, and Ipsen; and stock ownership in UCB. SA reports membership of advisory boards or boards of directors for MSD, Roche, Bristol Myers Squibb, Pfizer, Ipsen, Galapagos, AstraZeneca, Astellas, Amgen, BeOne, Regeneron and Lilly, and institutional research support from CSL Behring and Octapharma. All payments were made to institutional or research accounts and not to SA personally. AV reports speaker, advisory board and congress fees from Novartis, MSD and Ipsen, all paid directly to UZA. AVs spouse works as a freelancer for LynxCare Health. The remaining authors declare no competing interests. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The Ethics Committee of Antwerp University Hospital (Universitair Ziekenhuis Antwerpen), Belgium, granted ethical approval for this retrospective multicenter study (reference UZA7026). The requirement for individual informed consent was waived. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability The patient-level data used in this study are not publicly available because they contain sensitive health information and are subject to institutional and data governance restrictions. Aggregated results from the FAIR-ICI cohort can be explored through the publicly accessible interactive dashboard at FAIR-ICI dashboard link. Further information regarding access to the underlying data may be obtained from the corresponding author, subject to applicable ethical, institutional, and data-sharing requirements. ## Funder Information Declared Kom op tegen Kanker Stichting tegen Kanker, https://ror.org/01h3dr788 European Society for Medical Oncology, https://ror.org/03xtz2n86 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.11.02.26367076v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.11.02.26365310v1 "Screening for rheumatoid arthritis-associated interstitial lung disease using lung ultrasound: a systematic review and quality appraisal of recent studies") Posted November 03, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.11.02.26367076v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/11/03/2026.11.02.26367076.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.11.02.26367076v1#p-5) [Supplementary Material ](https://www.medrxiv.org/content/10.64898/2026.11.02.26367076v1.supplementary-material) [ Data/Code](https://www.medrxiv.org/content/early/2026/11/03/2026.11.02.26367076.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Comprehensive real-world utilization, treatment trajectories, and outcomes of immune checkpoint inhibitors across cancer types: the multicenter FAIR-ICI cohort Linh T. Ha, Fabienne Ver Donck, Iege Bassez, Clara L. Oeste, Christof Vulsteke, Danielle Delombaerde, Dries Hens, Hans Prenen, Lieselot Croes, Astrid De Meulenaere, Philip R. Debruyne, Marthe Verhaert, Sandrine Aspeslagh, Nele Brusselaers, Annelies Verbiest medRxiv 2026.11.02.26367076; doi: https://doi.org/10.64898/2026.11.02.26367076 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.02.26367076v1%26text%3DComprehensive%2520real-world%2520utilization%252C%2520treatment%2520trajectories%252C%2520and%2520outcomes%2520of%2520immune%2520checkpoint%2520inhibitors%2520across%2520cancer%2520types%253A%2520the%2520multicenter%2520FAIR-ICI%2520cohort "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.02.26367076v1%26t%3DComprehensive%2520real-world%2520utilization%252C%2520treatment%2520trajectories%252C%2520and%2520outcomes%2520of%2520immune%2520checkpoint%2520inhibitors%2520across%2520cancer%2520types%253A%2520the%2520multicenter%2520FAIR-ICI%2520cohort "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.me
## Related Clinical Research

- [Cancer vaccines and neoantigen strategies in the immunotherapy era](https://medichelpline.com/clinical-feed/nature-reviews-clinical-oncology-1-cancer-vaccines-in-the-era-of-immunotherapy-from-antigen-delivery-to-immune.md)
- [FDA Oncology Approvals 2014–2025: Immunotherapy vs Non‑Immunotherapy Endpoints and Efficacy](https://medichelpline.com/clinical-feed/medrxiv-1-usfda-oncology-drug-approvals-from-2014-2025-comparing-non-immunotherapy-and.md)
- [53L10 T‑cell engager tribody for immunotherapy of multiple solid tumors — Frontiers in Immunology](https://medichelpline.com/clinical-feed/frontiers-in-immunology-11-53l10-t-cell-engager-tribody-for-immunotherapy-of-multiple-solid-tumors.md)
- [Polymer-Based Drug Delivery Targeting the Tumor Microenvironment for Immunotherapy of Triple-Negat](https://medichelpline.com/clinical-feed/frontiers-in-immunology-14-advancements-in-polymer-based-drug-delivery-systems-targeting-the-tumor.md)
- [Immune-pressure redistribution as a framework for resistance to PD-1/PD-L1 blockade](https://medichelpline.com/clinical-feed/pubmed-42763389.md) (DOI: 10.1186/s12943-026-02786-4)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.